Company: STAA
Filing Date: 2025-03-18
Form Type: 8-K
Source: 0000950170-25-040620
Chunk: 0

Company: STAAR SURGICAL CO
Filing Date: 2025-03-18
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 17, 2025, STAAR Surgical Company (the “ Company”) announced a realignment of its leadership structure. The Company announced that its Board of Directors (the “ Board”) appointed the Company’s Chief Operating Officer, Warren Foust, as President and Chief Operating Officer of the Company, effective March 17, 2025 (the “ Effective Date”). In addition, the Company announced that the Board appointed Deborah Andrews, the Company’s former Chief Financial Officer, to serve as the Company’s Interim Chief Financial Officer and principal accounting officer on an interim basis, effective as of the Effective Date, and that Patrick Williams has agreed to step down, effective as of the same date, at the request of the Board from his position as Chief Financial Officer. The Board will be initiating a search for a permanent Chief Financial Officer. Effective as of the Effective Date, the Board appointed Magda Michna, PhD, the Company’s Chief Clinical, Regulatory and Medical Affairs Officer, to the newly created role of Chief Development Officer, reporting to Mr. Foust. In this expanded role, Dr. Michna will continue to oversee the Company’s clinical, regulatory, and medical affairs functions, and she will assume additional responsibility for the Company’s quality and research and development (“ R& D”) functions. In connection with Dr. Michna’s promotion, Keith Holliday, PhD has agreed to retire, effective as of the Effective Date, at the request of the Board from his position as Chief Technology Officer and head of the Company’s R& D function.

Mr. Foust, age 49, joined the Company in April 2023 as Chief Operating Officer. Prior to joining the Company, Mr. Foust served as Worldwide President, Johnson & Johnson Vision, Surgical, from December 2019 to April 2023. Prior to Johnson & Johnson Vision, Surgical, he served as Worldwide President of Mentor, a leading breast reconstruction and aesthetics business unit of Johnson & Johnson from 2018 to 2019, and Vice President, U. S. Sales and Marketing from 2015 to 2018. Prior to Mentor, Mr. Foust held various sales leadership roles at DePuy Synthes, also a company of Johnson & Johnson. He started his career at Roche Pharmaceuticals as a sales representative in 1999. Mr. Foust holds a Master’s Degree